5 Radiobiology of LDR, HDR, PDR and VLDR Brachytherapy

Radiobiology of LDR, HDR, PDR and VLDR Brachytherapy

19

THE GEC ESTROHANDBOOKOF BRACHYTHERAPY | Part I: The Basics of Brachytherapy Version 1 - 22/10/2015

spective randomized trial comparing two BT low dose rates in cervical carci- nomas. Int J Radiat Oncol Biol Phys 1994; 29: 953-60. 48. Hall EJ, Bedford JS: Dose rate: its effect on the survival of HeLa cells irradiated with gamma rays. Radiat Res 1964; 22: 305-15. 49. Hammer J, Seewald DH, Track C, et al. Breast cancer: primary treatment with external-beam radiation therapy and high-dose-rate iridium implantation. 50. Radiology 1994;193:573–7.Harms W, Krempien R, Hensley FW, Berns C, Wannenmacher M, Fritz P. Results of chest wall reirradiation using pulsed- dose-rate (PDR) BT molds for breast cancer local recurrences. Int J Radiat Oncol Biol Phys 2001; 49: 205-10. 51. Harms W, Krempien R, Hensley FW, Berns C, Fritz P, Wannenmacher M. 5 –year results of pulsed dose rate BT applied as a boost after breast-conserving therapy in patients at high risk for local recurrence from breast cancer. Strahl- enther Onkol 2002; 178: 607-14 52. Harms W, Krempien R, Grehn C et al . Daytime pulsed dose rate BT as a new treatment option for previouwly irradiated patients with recurrent oesopha- geal cancer. BJR 2005; 78: 236-241. 53. Haustermans K, Fowler J, Landuyt W, et al . Is pulsed dose rate more damaging to spinal cord of rats than continuous low dose rate? Radiother Oncol 1997; 45: 39-47. 54. Herstein, A.; Wallner, K.; Merrick, G.; Mitsuyama, H; Armstrong, J.; True, L. Cavanagh, W. Butler, W.: I‐125 Versus Pd‐103 for Low‐Risk Prostate Cancer: Long‐Term Morbidity Outcomes From a Prospective Randomized Multi- center Controlled Trial. Cancer Journal : 2005 - 11 - 5 - 385–389 55. HopewellJW.,Nyman,J.Turesson,I. Time factor for acute tissue reactions following fractionated irradiation: a balance between repopulation and en- hanced radiosensitivity. Int J Radiat Biol. 2003 Jul; 79(7):513-24. 56. Horiot JC, Pourquier H, Schraub S, et al . Current status of the management of cancer of the cervix in daily practice and in clinical research. I, Mould RF (ed) B rachytherapy 2. Nucletron International. Leersum 1989 pp 199-214 57. Hoskin PJ, Rojas AM, Bownes PJ, Lowe GJ, Ostler PJ, Bryant L. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. RadiotherOncol. 2012; 103: 217-222 58. Hoskin P, Rojas A, Lowe G, Bryant L, Ostler P, Hughes R, Milner J, Cladd H High-dose-rate brachytherapy alone for localized prostate cancer in patients at moderate or high risk of biochemical recurrenceInt J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):1376-84. 59. Hunter RD. Dose rate correction in LDR intracavitary therapy. In: Mould RF, Battermann JJ, editors. BT. From radium to optimization. Nucletron Interna- tional 1994. BV. Veenendaal. The Netherlands. 60. Inoue T, Inoue T, Teshima T, Murayam S, et al . Phase III trial of high and low dose rate interstitial radiotherapy for early oral tongue cancer. Int J Radiat Oncol Biol Phys 1996; 36: 1201-6. 61. Inoue T, Inoue T, Yamazaki H, et al . High dose rate versus low dose rate inter- stitial radiotherapy for carcinoma of the floor of mouth. Int J Radiat Oncol Biol Phys 1998; 41: 53-8. 62. International Commission on Radiation Units and Measurements. Dose and volume specification for reporting intracavitary therapy in gynecology. Re- port 38 1985; Bethesda. 63. ICRU Report 50. Prescribing Recording, and Reporting Photon Beam Thera- py. International Commission on Radiation Units and Measurements (1993). 7910 Woodmont Avenue, Bethesda, MD 20814, USA. 64. ICRU Report 62. Prescribing Recording, and Reporting Photon Beam Thera- py (supplement to ICRU Report 50). International Commission on Radiation Units and Measurements (1999). 7910 Woodmont Avenue, Bethesda, MD 20814, USA. 65. ICRU Report 83. Prescribing Recording, and Reporting Photon-Beam Inten- sity-Modulated Radiation therapy (IMRT) (2010). 7910 Woodmont Avenue, Bethesda, MD 20814, USA 66. ICRU report 88 Prescribing Recording, and Reporting Brachytherapy for can- cer of the Cervix (2015). 7910 Woodmont Avenue, Bethesda, MD 20814, USA 67. Johansson B, Karlsson L, Liljegren G, Hardell L, Persliden J. Pulsed dose rate BT as the sole adjuvant radiotherapy after breast –conserving surgery of T1- T2 breast cancer: First long time results from a clinical study. Radiother Oncol

2009; 90: 30-35. 68. Johansson B, Karlsson L, Reizenstein R, von Beckerath M Hardell L, Persliden J. Pulsed dose rate brachytherapy as the boost in combination with external beam irradiation in base of tongue cancer. Long term results from a uniform clinical series. J. of Contemp Brachyther ;2011: 3,1. 11-17) 69. Joiner M 2009 Quantifying cell kill and cell survival in Basic Clinical Radiobi- ology. 4th Edition. Hodder Arnold 2009 pp41-55 70. Joinerr M, van der Kogel A Steel G. Introduction:the significance of radiobi- ology and radiotherapy for cancer treatment Basic Clinical Radiobiology. 4th Edition. Hodderrnold 2009 pp1-10 71. King CR. What is the T-pot for prostate cancer? Radiobiological implications of the equivalent outcome with I -125 or Palladium -103 . Int J Radiat Oncol Biol Phys 2000; 47(5) 1165-1167 72. Kirkpatrick JP,Meyer JJ, Marks LB. The Linear-quadratic model is inappro- priate to model high doses per fraction effects in radiosurgery. Seminars in Radiation Oncology 2008; 18: 240-243 73. Kovacs G,,Galalea R, Loch T, Bertermann H, Kohr P, Schneider R, Kiming B. Prostate presevation by combined external beam and HDR brachytherapy in node negative prostate cancer. Strahlenther . Onkol . 1999: 175 S2 87-8 74. Kutcher GJ, Burman C. Calculation of complication probability factors for non-uniform normal tissue irradiation: the effective volume method. Int J Ra- diat Oncol Biol Phys. 1989 Jun; 16(6):1623-30. 75. Larra F, Dixon B, Couette JE, et al . Facteur temps en curiethérapie ; J Radiol Electrol 1 977; 58: 329-33. 76. Lau HY, Hay JH, Flores AD, Threlfall WJ. Seven fractions of twice daily high dose-rate BT for node-negative carcinoma of the mobile tongue results in loss of therapeutic ratio. Radiother Oncol 1996; 39: 15-8. 77. Leborgne F, Fowler JF, Leborgne JH, et al . Fractionation in medium dose rate BT of cancer of the cervix. Int J Radiat Oncol Biol Phys 1996; 35: 907-14. 78. Leborgne F, Fowler JF, Leborgne JH, et al . Medium-dose-rate BT of cancer of the cervix: preliminary results of a prospectively designed schedule based on the linear-quadratic model. Int J Radiat Oncol Biol Phys 1999; 43: 1061-4. 79. Leung T-W, Wong V Y-W, Kwan K-H, Ng T Y, Wong C M, Tung SY, Leung L.C. High dose rate brachytherapy for early stage oral tongue cancer . Head & Neck 20 02: 24(1) 274-281 80. Levendag PC, Schmitz PI, Jansen PP, Senan S, Eijkenboom WM, Sipkema D, Meeuwis CA Kolkman-Deurloo IK Visser AG. Fractionated high-dose rate and pulsed-dose rate BT: First clinical experience in squamous cell carcinoma of the tonsillar fossa and hard palate. Int J Radiat Oncol Biol Phys 1997; 38: 497-506. 81. Ling CC, Spiro IJ, Mitchell J, Stickler BA. The variation of OER with dose rate. Int J Radiat Oncol Biol Phys 1985; 11: 1367-73. 82. Ling CC, Li WX, Anderson LL. The relative effectiveness of I -125 and PD -103 . Int J Radiat Oncol Biol Phys 2000 12 (2): 373-378. 83. Mansfield C.M, Komarnicky L.T, Schwartz G.F, Rosenberg A, Krishnan L, Jewil W l, et al .Ten year results in 1070 patients with stages I and II breast cancer treated by conservative surgeryand radiation therapy. Cancer , 1995: 75. 2328–2336 84. Marks LB Use of normal tissue complication probability models in the clinic.” Int J Radiat Oncol Biol Phys . 2010; 76(3 Suppl):S10-9.) 85. Martinez AA, Gonzalez J, Ye H et al . Dose escalation improves cancer related events at 10 years for intermediate and high risk prostate cancer patients treat- ed with hypofractionated high dose rate boost and external beam radiothera- py. Int J RadiatOncolBiolPhys 2011; 79: 363-370 86. Mason KA, Thames HD, Ochran TG, et al. Comparison of continuous and pulsed low dose rate BT: biological equivalence in vivo. Int J Radiat Oncol Biol Phys 1994; 28: 667-71. 87. Mazeron JJ, Simon JM, Crook J, et al . Influence of dose rate on local control of breast carcinomas treated by external beam irradiation plus iridium 192. Int J Radiat Oncol Biol Phys 1991; 21: 1173-77. 88. Mazeron JJ, Simon JM, Le Péchoux C, et al . Effect of dose rate on local control and complications in definitive irradiation of T1-2 squamous cell carcinomas of mobile tongue andfloor of mouth with interstitial 192. Radiother Oncol 1991; 21: 39-47.